The Cyprus Institute of Neurology and Genetics (CING) has become an integral partner in the European PoCCardio research project, an ambitious initiative designed to enhance the prediction and prevention of myocardial infarctions. This collaboration unites premier research institutions from across the continent in a bid to develop refined, individualised diagnostic tools for cardiovascular disease.
Project Overview And Funding
Titled Personalised Medicine by Using an Advanced Point-Of-Care Tool for Stratified Treatment In High Risk Cardiovascular Patients, the project is set to enroll 1,800 patients with a history of heart attacks in clinical trials. These trials focus on collecting essential medical data and biomarker measurements, thereby advancing diagnostic accuracy and prognostic assessment for heart conditions. The initiative is backed by a robust €14 million budget from the European Union’s Horizon Europe programme, with CING securing €540,000 to support its contribution.
Follow THE FUTURE on LinkedIn, Facebook, Instagram, X and Telegram
Strategic Partnership And Expertise
CING has joined PoCCardio under the Horizon Europe “Hop-on Facility,” part of the program’s Widening Participation and Spreading Excellence initiative. This move allows research institutions from developing countries to engage in forefront research and innovation. Leading the institute’s contribution, the Department of Bioinformatics, well-versed in computational diagnostics and therapeutics, operates under the expert guidance of Associate Scientist Dr Anastasios Oulas. Dr Oulas emphasized that modern bioinformatics is key to predicting myocardial infarction risks, enabling timely, personalised treatments for patients.
Bridging Technical And Clinical Expertise
Professor Hans Peter Dimai, the project coordinator from the Medical University of Graz, hailed CING’s participation. He highlighted the role of CING’s Department of Bioinformatics as a crucial bridge between clinical experience and technical innovation, particularly through Systems Bioinformatics, which is essential for predicting high-risk patients and refining treatment responses.
Innovative Diagnostic Integration
Within the PoCCardio framework, CING’s team will harness advanced network generation tools to map clinically significant interactions among biomarkers. This process involves creating complex networks from genomic and proteomic data alongside publicly available datasets detailing proteins and gene polymorphisms linked to cardiovascular conditions. The resulting algorithms will bolster the prediction of myocardial infarction risks. Furthermore, the department aims to develop a diagnostic protocol that integrates enriched biomarker measurements with data from a point-of-care device, thus streamlining rapid and cost-effective analysis using state-of-the-art artificial intelligence.
Advancing European Research Excellence
CING’s engagement in PoCCardio not only cements its role as a key player in cutting-edge European research but also reinforces Horizon Europe’s overarching mission to enhance innovation and research excellence across the continent. The collaborative efforts promise to yield significant advancements in cardiovascular patient care and diagnostic services.
